Judge: FDA Ignored Evidence in ‘Deeming’ Premium Cigars

Events
Jul.07.2022

The U.S. Food and Drug Administration ignored evidence about health risks in considering premium cigars to be subject to same law as cigarettes, a federal judge ruled on July 5, reports Reuters.  

Judge: FDA Ignored Evidence in ‘Deeming’ Premium Cigars

The litigation focuses on the 2016 Deeming Rule, in which the agency identified a wide range of tobacco products, including premium cigars, to be subject to its regulatory authority along with cigarettes under the Family Smoking Prevention and Tobacco Control Act.

 

The FDA rule requires cigar makers to register their products annually, provide ingredient lists for each product and submit products for laboratory testing—procedures the premium cigar industry considers impractical for its handmade, “artisan” products.

 

The Premium Cigar Association and Cigar Rights of America challenged the Deeming Rule, arguing that, unlike cigarettes and e-cigarettes, premium cigars do not appeal to young people and are not associated with addiction. They cited studies showing that young people are unlikely to use premium cigars, that users of premium cigars are unlikely to smoke them frequently and that infrequent cigar use is not associated with increased mortality.

 

U.S. District Judge Amit Mehta in Washington DC agreed that the FDA had not adequately considered the studies cited by the plaintiffs, instead asserting that there was “no evidence” that premium cigars were less harmful.

 

“Where, as here, an agency speaks in absolute terms that there is no evidence, it acts arbitrarily and capriciously when there is in fact pertinent record evidence and the agency ignores or overlooks it,” the judge wrote.

 

Judge Mehta asked the FDA and the industry groups to submit briefs on whether he should vacate the FDA’s decision or simply remand the matter back to the agency.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

UPC Court of Appeal refuses to revive VMR’s European vape patent, upholding lack of inventiveness
UPC Court of Appeal refuses to revive VMR’s European vape patent, upholding lack of inventiveness
The Unified Patent Court’s Court of Appeal declined on Dec. 29 to revive a European patent held by VMR Products LLC, upholding a finding that the patent is not inventive over earlier devices. The decision said adding a window in the vape’s outer shell to reveal the internal cartridge holding vape liquid was an obvious, routine adaptation based on an earlier U.S. patent and general knowledge.
Jan.06 by 2FIRSTS.ai
Thailand’s Bangkok Police Bust Two Warehouses, Seize Over 100,000 Heated-Tobacco Items Worth $960,000
Thailand’s Bangkok Police Bust Two Warehouses, Seize Over 100,000 Heated-Tobacco Items Worth $960,000
Bangkok police said they raided two warehouse locations linked to an online distribution network for illicit vaping/heated-tobacco products, seizing IQOS ILUMA i devices and large quantities of TEREA sticks worth more than 30 million baht (about US$960,000). Three suspects described as administrators and caretakers were arrested, while investigators probe suspected smuggling routes and unpaid excise liabilities.
Feb.02 by 2FIRSTS.ai
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
British American Tobacco (BAT) CEO Tadeu Marroco said the group will continue to invest in equipment and technology in Italy and expand capacity for next-generation tobacco products such as e-cigarettes and heated tobacco. BAT’s Trieste innovation hub is slated to receive a total investment of 500 million euros by 2027 and add 16 new production lines.
Feb.03 by 2FIRSTS.ai
2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
2Firsts Outlines 2026 Global Product Trends in the New Tobacco Industry
As regulation tightens and innovation matures, competition in the new tobacco industry is shifting. In its 2026 Global Product Trends in the New Tobacco Industry report, 2Firsts examines how heated tobacco, nicotine pouches, and vape products are moving beyond feature-driven upgrades toward system-level design, where experience management, compliance structure, and engineering capability increasingly shape long-term competition.
Jan.13 by 2Firsts Perspectives
Germany Sees 18.2% Jump in Taxed Tobacco Substitutes in 2025, Including E-liquids
Germany Sees 18.2% Jump in Taxed Tobacco Substitutes in 2025, Including E-liquids
Germany’s Federal Statistical Office (Destatis) said 66.4 billion cigarettes were taxed in 2025, up 0.2% from 2024, while long-term volumes have more than halved since 1991 and per-capita consumption fell to 795 cigarettes. Taxed tobacco substitutes such as e-cigarette liquids reached 1.5 million liters, up 18.2% year on year.
Jan.26 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24